MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Exelixis Net Debt 2011-2025 | EXEL
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Exelixis
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.54 M | -47.3 M | -295 M | -607 M | -212 M | -216 M | -315 M | -169 M | -142 M | 265 M | 281 M | 243 M | -170 M | 107 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 281 M | -607 M | -91.2 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.9 | 4.03 % | $ 813 M |  Canada |
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
-22 M | $ 3.21 | -1.38 % | $ 248 M |  USA |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-3.28 M | $ 1.06 | -6.22 % | $ 293 K | USA |
 |
Catalyst Biosciences
CBIO
|
-33.1 M | $ 13.33 | -5.39 % | $ 878 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-195 M | $ 214.55 | -2.66 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.1 | -5.93 % | $ 7.46 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
-24.5 M | $ 27.09 | -1.53 % | $ 1.74 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
-121 M | $ 88.51 | 0.59 % | $ 9.14 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
-514 M | $ 24.35 | 3.07 % | $ 2.88 B | USA |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
CureVac N.V.
CVAC
|
-783 M | $ 5.02 | -0.59 % | $ 934 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
-17.2 M | $ 1.43 | -1.72 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
-973 M | $ 93.99 | -0.86 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-65.3 M | $ 10.88 | 0.74 % | $ 1.41 B | USA |
 |
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 26.44 | 4.63 % | $ 1.28 B | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-46 M | $ 9.6 | 0.42 % | $ 141 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-10.8 M | $ 15.97 | -4.37 % | $ 410 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 0.26 | -6.9 % | $ 566 M |  Israel |
 |
Evogene Ltd.
EVGN
|
-3.44 M | $ 1.04 | -3.7 % | $ 27.9 M | Israel |
 |
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |
|
Foghorn Therapeutics
FHTX
|
-18.3 M | $ 4.39 | -1.13 % | $ 241 M | USA |
 |
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
-404 M | $ 551.37 | -2.29 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-19.9 M | $ 2.35 | 2.17 % | $ 14.8 M | USA |
 |
AstraZeneca PLC
AZN
|
9.86 B | $ 91.19 | 1.51 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
-135 M | $ 8.88 | -1.33 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 11.25 | -2.43 % | $ 728 M | USA |
 |
Biogen
BIIB
|
4.01 B | $ 174.69 | 0.34 % | $ 25.4 B | USA |